Despite Trulicity success, Lilly can't escape diabetes concerns

Eli Lilly reported $6.06 billion worth of revenue for the third quarter, a 7% increase from the same period a year prior. Key to that growth were products launched in the last several years, including Type 2 diabetes medicine Trulicity and anti-inflammation agent Taltz.